Jennifer K. Litton

22.4k total citations · 5 hit papers
238 papers, 11.1k citations indexed

About

Jennifer K. Litton is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Jennifer K. Litton has authored 238 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 170 papers in Oncology, 98 papers in Cancer Research and 97 papers in Genetics. Recurrent topics in Jennifer K. Litton's work include BRCA gene mutations in cancer (88 papers), Breast Cancer Treatment Studies (59 papers) and PARP inhibition in cancer therapy (57 papers). Jennifer K. Litton is often cited by papers focused on BRCA gene mutations in cancer (88 papers), Breast Cancer Treatment Studies (59 papers) and PARP inhibition in cancer therapy (57 papers). Jennifer K. Litton collaborates with scholars based in United States, United Kingdom and Spain. Jennifer K. Litton's co-authors include Gabriel N. Hortobágyi, Banu Arun, Funda Meric‐Bernstam, Ana M. González-Angulo, Elizabeth A. Mittendorf, Archie Bleyer, Rebecca H. Johnson, Carey K. Anders, Hope S. Rugo and Marianne Phillips and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Jennifer K. Litton

225 papers receiving 10.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →
PD-L1 Expression in Triple-Negative Breast Cancer

2014 1.1k citations Elizabeth A. Mittendorf, Anne V. Philips et al. Cancer Immunology Research profile →
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

2017 768 citations Shiping Jiao, Weiya Xia et al. Clinical Cancer Research profile →
Breast Cancer Before Age 40 Years

2009 563 citations Jennifer K. Litton et al. profile →
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer K. Litton United States	49	7.7k	3.8k	3.2k	2.5k	2.4k	238	11.1k
Tomofumi Osako Japan	19	6.0k 0.8×	5.7k 1.5×	5.2k 1.7×	1.6k 0.6×	2.2k 1.0×	42	12.1k
Rebecca Dent Singapore	44	6.5k 0.8×	4.1k 1.1×	3.0k 0.9×	1.2k 0.5×	2.4k 1.0×	186	10.2k
Mamiko Fujisue Japan	11	5.5k 0.7×	5.4k 1.4×	5.1k 1.6×	1.5k 0.6×	2.1k 0.9×	18	11.4k
Yasuo Toyozumi Japan	14	5.8k 0.8×	5.5k 1.5×	5.2k 1.6×	1.5k 0.6×	2.2k 0.9×	37	11.8k
Binghe Xu China	41	6.1k 0.8×	3.0k 0.8×	3.2k 1.0×	1.2k 0.5×	2.8k 1.2×	387	9.1k
Rumiko Tashima Japan	10	5.6k 0.7×	5.4k 1.4×	5.1k 1.6×	1.5k 0.6×	2.1k 0.9×	21	11.5k
Reiki Nishimura Japan	27	6.8k 0.9×	6.2k 1.7×	5.4k 1.7×	1.8k 0.7×	2.6k 1.1×	131	13.3k
Anthony Gonçalvès France	45	6.2k 0.8×	2.3k 0.6×	2.8k 0.9×	953 0.4×	3.0k 1.3×	318	9.5k
Aleix Prat Spain	55	8.9k 1.2×	6.1k 1.6×	5.8k 1.8×	1.2k 0.5×	3.5k 1.5×	395	14.7k
Chad Livasy United States	35	6.6k 0.9×	6.0k 1.6×	3.9k 1.2×	1.4k 0.5×	1.8k 0.8×	95	11.3k

Countries citing papers authored by Jennifer K. Litton

Since Specialization

Citations

This map shows the geographic impact of Jennifer K. Litton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer K. Litton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer K. Litton more than expected).

Fields of papers citing papers by Jennifer K. Litton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer K. Litton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer K. Litton. The network helps show where Jennifer K. Litton may publish in the future.

Co-authorship network of co-authors of Jennifer K. Litton

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer K. Litton. A scholar is included among the top collaborators of Jennifer K. Litton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer K. Litton. Jennifer K. Litton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garber, Haven R., Sreyashi Basu, Sonali Jindal, et al.. (2024). Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 15(1). 238–247. 2 indexed citations

Damodaran, Senthil, Diane Liu, Jill L. Schwartz, et al.. (2023). Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). Cancer Research. 83(5_Supplement). P3–2. 2 indexed citations

Wu, Chengyue, Angela M. Jarrett, Zijian Zhou, et al.. (2022). MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer Research. 82(18). 3394–3404. 45 indexed citations

Liu, Xuan, Zhongqi Ge, Fei Yang, et al.. (2022). Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. npj Breast Cancer. 8(1). 64–64. 5 indexed citations

Yam, Clinton, Gaiane M. Rauch, Meghan Karuturi, et al.. (2020). A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs. 39(2). 509–515. 24 indexed citations

Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 31(11). 1526–1535. 252 indexed citations breakdown →

Litton, Jennifer K., HS Rugo, Johannes Ettl, et al.. (2018). Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. Cancer Research. 78(4_Supplement). GS6–7. 40 indexed citations

Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763. 1401 indexed citations breakdown →

Clifton, Katherine, et al.. (2018). Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. The Breast Journal. 24(4). 691–692. 8 indexed citations

10.

Fujii, T., Takahiro Kogawa, Wanli Dong, et al.. (2017). Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology. 28(10). 2420–2428. 110 indexed citations

11.

Rugo, Hope S., Lasika Seneviratne, J. Thaddeus Beck, et al.. (2017). Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. The Lancet Oncology. 18(5). 654–662. 145 indexed citations

12.

Carey, Jason P.W., Cansu Karakaş, Tuyen Bui, et al.. (2017). Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Research. 78(3). 742–757. 103 indexed citations

13.

Evans, Kurt W., Erkan Yuca, Argun Akçakanat, et al.. (2017). A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clinical Cancer Research. 23(21). 6468–6477. 48 indexed citations

14.

Jiao, Shiping, Weiya Xia, Hirohito Yamaguchi, et al.. (2017). PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research. 23(14). 3711–3720. 768 indexed citations breakdown →

15.

Mittendorf, Elizabeth A., Alexandros Ardavanis, James T. Symanowski, et al.. (2016). Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Annals of Oncology. 27(7). 1241–1248. 80 indexed citations

16.

Parinyanitikul, Napa, Xiudong Lei, Mariana Chávez‐MacGregor, et al.. (2014). Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer. 15(2). 153–160. 35 indexed citations

17.

Mittendorf, Elizabeth A., Anne V. Philips, Funda Meric‐Bernstam, et al.. (2014). PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunology Research. 2(4). 361–370. 1065 indexed citations breakdown →

18.

Yennurajalingam, Sriram, Susan Frisbee‐Hume, J. Lynn Palmer, et al.. (2013). Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer. Journal of Clinical Oncology. 31(25). 3076–3082. 228 indexed citations

19.

Dawood, Shaheenah, Xiudong Lei, Jennifer K. Litton, et al.. (2012). Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer. Cancer. 118(19). 4652–4659. 64 indexed citations

20.

Beadle, Beth M., Wendy A. Woodward, Lavinia P. Middleton, et al.. (2009). The impact of pregnancy on breast cancer outcomes in women ≤35 years. Cancer. 115(6). 1174–1184. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact